Janet Woodcock (AP Images)

Why the Biden ad­min­is­tra­tion might not want to be con­tent with just an act­ing FDA com­mis­sion­er

An­oth­er month has passed with­out Pres­i­dent Joe Biden nom­i­nat­ing any­one to fill the per­ma­nent FDA com­mis­sion­er po­si­tion, and ex­perts are con­tin­u­ing to raise con­cerns about what it means for the agency to not have a Sen­ate-ap­proved leader dur­ing a once-in-a-life­time pan­dem­ic.

The push to fill the top spot at the FDA once seemed like a two-per­son race be­tween act­ing com­mis­sion­er Janet Wood­cock, an in­dus­try and FDA in­sid­er fa­vorite who has ruf­fled some feath­ers among Sen­ate De­moc­rats, and for­mer prin­ci­pal deputy com­mis­sion­er of FDA Josh Sharf­stein, who’s now a vice dean and pro­fes­sor at Johns Hop­kins.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.